COSMOS Pharmaceutical Corporation
CSMYF · OTC
5/31/2025 | 5/31/2024 | 5/31/2023 | 5/31/2022 | |
|---|---|---|---|---|
| Market Cap | $524 | $612 | $271 | $250 |
| - Cash | $57 | $52 | $46 | $37 |
| + Debt | $50 | $34 | $18 | $9 |
| Enterprise Value | $517 | $594 | $244 | $222 |
| Revenue | $1,011 | $965 | $828 | $755 |
| % Growth | 4.8% | 16.6% | 9.6% | – |
| Gross Profit | $213 | $188 | $169 | $151 |
| % Margin | 21.1% | 19.5% | 20.4% | 20% |
| EBITDA | $65 | $54 | $50 | $48 |
| % Margin | 6.4% | 5.6% | 6.1% | 6.4% |
| Net Income | $31 | $24 | $24 | $23 |
| % Margin | 3.1% | 2.5% | 2.9% | 3.1% |
| EPS Diluted | 390.86 | 308.61 | 600.95 | 584.74 |
| % Growth | 26.7% | -48.6% | 2.8% | – |
| Operating Cash Flow | $52 | $55 | $54 | $32 |
| Capital Expenditures | -$53 | -$56 | -$47 | -$43 |
| Free Cash Flow | -$1 | -$1 | $8 | -$11 |